Top brand choice
Strength | Pack Size | Qty | |
---|---|---|---|
Strength
25mg
|
|||
Strength
100mg
|
We guarantee the lowest price on all of our prescription products. If you find your medications cheaper at any other recognized licensed mail order pharmacy, we will not only match their price, we will beat it by 25% of the difference. It is our 125% price match guarantee!
Example: If you find a product on Canada Drugs Direct for $50.00 and find the same product for $40.00 at another mail order pharmacy, we will provide you with a $12.50 discount, bringing your total to $37.50.
To get the discount please make sure to mention the price match to the customer service team when they call to collect payment for your order. Or call toll free at 1-888-904-8467 to place the order through the phone.
Terms & Conditions of Program
A generic drug is a copy of the brand-name drug with the same dosage, safety, strength, quality, consumption method, performance, and intended use. Before generics become available on the market, the generic company must prove it has the same active ingredients as the brand-name drug and works in the same way and in the same amount of time in the body.
The only differences between generics and their brand-name counterparts is that generics are less expensive and may look slightly different (eg. different shape or color), as trademarks laws prevent a generic from looking exactly like the brand-name drug.
Generics are less expensive because generic manufacturers don't have to invest large sums of money to develop a drug. When the brand-name patent expires, generic companies can manufacture a copy of the brand-name and sell it at a substantial discount.
Your doctor may prescribe Vitrakv if you have certain types of cancer. It is approved for solid tumors with a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without known acquired resistance mutations. This drug is used when the cancer has metastasized or where surgical resection would likely lead to severe complications, especially when there are no alternative treatments.
Vitrakvi is a selective TRK inhibitor that targets and inhibits the activity of tropomyosin receptor kinases (TRKs), which play a role in the growth and spread of cancer cells with NTRK gene fusions. By blocking TRK activity, Vitrakvi helps prevent cancer cell growth and spread.
Fact Table | |
---|---|
Formula | C21H22F2N6O2 |
License | FDA approved |
Bioavailability | Approximately 34% |
Legal status | Prescription only |
Chemical Name | 5-[(2S)-2-[(2,5-Difluorophenoxy)methyl]pyrrolidin-1-yl]-N-(2,2-dimethylpropyl)-N'-hydroxy-1H-1,2,3-triazole-4-carboxamide |
Elimination half-life | Approximately 3 hours |
Dosage (Strength) | 25 mg, 100 mg capsules; 20 mg/mL oral solution |
Pregnancy | Not recommended; consult a healthcare provider |
Brands | Vitrakvi |
Protein binding | 70% |
PubChem CID | 54702882 |
MedlinePlus | a618057 |
ChEBI | 134852 |
ATC code | L01XE56 |
DrugBank | DB11986 |
KEGG | D11014 |
Routes of administration | Oral |
The usual dosage is 100 mg by mouth twice daily. The dosage may be reduced for younger patients.
The active ingredient in Vitrakvi is larotrectinib.
The most common drug-drug interactions include:
Regular monitoring of hepatic function is essential, as Vitrakvi can cause liver enzyme elevations.
Vitrakvi can cause fetal harm when administered to a pregnant woman. Women of reproductive potential should use effective contraception during treatment and for at least one week after the final dose.
Side effects of Vitrakvi may include:
Vitrakvi [package insert]. Stamford, CT: Loxo Oncology; November 2018.